Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$3.20
-$0.07(-2.46%)
At close: 4:00 PM EDT
$3.20
-$0.07(-2.46%)
Day’s Range― - ―
52-Week Range$2.17 - $6.44
Previous CloseN/A
Volume1.91M
Average Volume (3M)3.85M
Market Cap
$447.39M
Enterprise Value$273.45M
Total Cash (Recent Filing)$326.32M
Total Debt (Recent Filing)$35.75M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend Yield1310.82%
Share Statistics
EPS (TTM)-0.78
Shares Outstanding194,517,700
10 Day Avg. Volume3,477,618
30 Day Avg. Volume3,853,707
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue8.82K
Enterprise Value/Gross Profit-18.26
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$19.00Price Target Upside493.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
MASH Phase III ProgressInitiating a large global Phase III program advances pemvidutide toward a potential registration decision in MASH, a major disease area for the company. The defined site strategy, enrollment window, and readout plan provide a structured development path and support durable pipeline value.
AUD Clinical EfficacyPositive Phase II results across drinking behavior, abstinence, and the objective PEth biomarker strengthen evidence that pemvidutide may address AUD meaningfully. Consistency across endpoints supports regulatory discussions and creates a potential expansion path beyond the company’s liver-focused programs.
Capitalization And RunwayThe strengthened cash position and low leverage give Altimmune financial capacity to execute its lead MASH Phase III program without immediate reliance on additional capital. Funding through the planned 52-week readout supports continuity of development and reduces near-term solvency pressure.
Bears Say
Pre-Commercial LossesAltimmune has not established a commercial revenue base, while research and development spending produces substantial recurring losses and cash outflows. Until a candidate is approved and commercialized, the business remains dependent on financing or partnerships rather than internally generated operating cash.
Funding Gap For AUDThe current financing plan supports the MASH program but leaves a potential AUD pivotal trial dependent on royalties, debt, or strategic partnerships that are not guaranteed. This could delay development, increase financing complexity, or require additional dilution if non-dilutive sources are unavailable.
Clinical Execution RiskPemvidutide’s longer-term prospects still depend on tolerability management, competitive enrollment, and successful execution across multiple pivotal studies. GI discontinuations and lengthy timelines could increase development costs or delay validation, leaving the company exposed before definitive efficacy and regulatory outcomes.
Altimmune News
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.17 and its highest was $6.44 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $447.39M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 12, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.018.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of 1310.82%. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.13.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 194,517,700 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went down -2.333%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (493.75% Upside)
$19.00 (493.75% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 91%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 16.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.80%
12-Months-Change
Fundamentals
Return on Equity
-31.41%
Trailing 12-Months
Asset Growth
176.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Altimmune Inc
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$19.00
▲(493.75% Upside)
Technical Analysis
Galectin Therapeutics
―
Arcturus Therapeutics
―
Oramed Pharm
―
Sagimet Biosciences, Inc. Class A
―
BioAge Labs, Inc.
―
Ownership Overview
0.42% Insiders
9.34% Mutual Funds
0.80% Other Institutional Investors
75.48% Public Companies and
Individual Investors